Literature DB >> 23852546

mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.

F Guo1, J Li1, S Zhang1, W Du1, S Amarachintha1, J Sipple1, J Phelan2, H L Grimes2, Y Zheng1, Q Pang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23852546      PMCID： PMC3947286          DOI： 10.1038/leu.2013.215

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

Review 2.  Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis.

Authors:  Alix E Seif
Journal:  Cancer Genet       Date:  2011-05

3.  The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.

Authors:  Bao Hoang; Angelica Benavides; Yijiang Shi; Yonghui Yang; Patrick Frost; Joseph Gera; Alan Lichtenstein
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

Review 4.  The Akt-mTOR tango and its relevance to cancer.

Authors:  Nissim Hay
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

5.  Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

Authors:  C Evangelisti; F Ricci; P Tazzari; G Tabellini; M Battistelli; E Falcieri; F Chiarini; R Bortul; F Melchionda; P Pagliaro; A Pession; J A McCubrey; A M Martelli
Journal:  Leukemia       Date:  2011-02-18       Impact factor: 11.528

6.  Antileukemic activity of rapamycin in acute myeloid leukemia.

Authors:  Christian Récher; Odile Beyne-Rauzy; Cécile Demur; Gaëtan Chicanne; Cédric Dos Santos; Véronique Mansat-De Mas; David Benzaquen; Guy Laurent; Françoise Huguet; Bernard Payrastre
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

Review 7.  The multifaceted role of mTOR in cellular stress responses.

Authors:  Christopher G Proud
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

8.  A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Authors:  Alexander E Perl; Margaret T Kasner; Donald E Tsai; Dan T Vogl; Alison W Loren; Stephen J Schuster; David L Porter; Edward A Stadtmauer; Steven C Goldstein; Noelle V Frey; Sunita D Nasta; Elizabeth O Hexner; Jamil K Dierov; Cezary R Swider; Adam Bagg; Alan M Gewirtz; Martin Carroll; Selina M Luger
Journal:  Clin Cancer Res       Date:  2009-10-20       Impact factor: 12.531

Review 9.  Defining the role of mTOR in cancer.

Authors:  David A Guertin; David M Sabatini
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

10.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Authors:  Ker Yu; Lourdes Toral-Barza; Celine Shi; Wei-Guo Zhang; Judy Lucas; Boris Shor; Jamie Kim; Jeroen Verheijen; Kevin Curran; David J Malwitz; Derek C Cole; John Ellingboe; Semiramis Ayral-Kaloustian; Tarek S Mansour; James J Gibbons; Robert T Abraham; Pawel Nowak; Arie Zask
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701
View more
  12 in total

1.  mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.

Authors:  Andrew J Massey; Peter Stephens; Rebecca Rawlinson; Lauren McGurk; Ruth Plummer; Nicola J Curtin
Journal:  Mol Oncol       Date:  2015-08-25       Impact factor: 6.603

2.  Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.

Authors:  Fukun Guo
Journal:  J Oncobiomarkers       Date:  2014

Review 3.  Glutaminolysis and autophagy in cancer.

Authors:  Victor H Villar; Faten Merhi; Mojgan Djavaheri-Mergny; Raúl V Durán
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

4.  Advances in the understanding of Fanconi Anemia Complementation Group D2 Protein (FANCD2) in human cancer.

Authors:  Yihang Shen; Jun Zhang; Herbert Yu; Peiwen Fei
Journal:  Cancer Cell Microenviron       Date:  2015-09-07

5.  mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.

Authors:  Deborah Silvera; Amanda Ernlund; Rezina Arju; Eileen Connolly; Viviana Volta; Jinhua Wang; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2017-02-15       Impact factor: 4.272

6.  mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.

Authors:  Wei Mo; Qingxin Liu; Curtis Chun-Jen Lin; Hui Dai; Yang Peng; Yulong Liang; Guang Peng; Funda Meric-Bernstam; Gordon B Mills; Kaiyi Li; Shiaw-Yih Lin
Journal:  Clin Cancer Res       Date:  2015-11-06       Impact factor: 12.531

7.  TORC2 inhibition may boost DNA-damaging chemotherapy.

Authors:  Manuel Stucki
Journal:  Oncotarget       Date:  2015-01-20

8.  TORC2-a new player in genome stability.

Authors:  Ronit Weisman; Adiel Cohen; Susan M Gasser
Journal:  EMBO Mol Med       Date:  2014-08       Impact factor: 12.137

9.  Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

Authors:  Rania El Botty; Florence Coussy; Rana Hatem; Franck Assayag; Sophie Chateau-Joubert; Jean-Luc Servely; Sophie Leboucher; Charles Fouillade; Sophie Vacher; Bérengère Ouine; Aurélie Cartier; Leanne de Koning; Paul Cottu; Ivan Bièche; Elisabetta Marangoni
Journal:  Oncotarget       Date:  2018-07-03

Review 10.  Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy.

Authors:  Ziwen Wang; Yujung Huang; Jiqiang Zhang
Journal:  Cell Mol Biol Lett       Date:  2014-04-11       Impact factor: 5.787
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.